Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Shareholder Meeting (November 2020)
25 slides from Kazia Therapeutics's shareholder meeting presentation, Nov 6, 2020
Slide 1: Presentation to Annual General Meeting of Shareholders
Presentation to Annual General Meeting of Shareholders Dr James Garner Chief Executive Officer Sydney, NSW 6 November 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Rationale
Investment Rationale World-Class Asset in Brain Cancer Clear Path to Commercialisation Strong Corporate Story Paxalisib developed by Genentech, the world’s most successful cancer drug company Well-proven mechanism of action, with unique differentiating factor of brain penetration Strong scientific r
Slide 4: Investment Rationale: Paxalisib is...
Investment Rationale Paxalisib is… Ü In a pivotal study for registration Ü Well-funded Ü Diversified into other brain cancers Ü Attractive for partnering and and and
Slide 5: Agenda
Agenda Operational Report Financial Report Looking Ahead
Slide 6: A broad-based clinical program is underway across multiple forms of brain cancer
A broad-based clinical program is underway across multiple forms of brain cancer Glioblastoma Most common and most aggressive brain tumour Phase II NCT03522298 Glioblastoma (planned pivotal study for approval [in set-up]) Phase II / III NCT03970447 Brain Metastases Cancer that has spread from any pr
Slide 7: Data read-outs this year have been highly encouraging
Data read-outs this year have been highly encouraging Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like Progression-Free Survival (PFS) Overall Survival (OS) 8.5 months Median PFS 5.3 months Median P
Slide 8: GBM AGILE is the planned pivotal study for paxalisib in glioblastoma
GBM AGILE is the planned pivotal study for paxalisib in glioblastoma What is GBM AGILE? Who is Behind It? A ‘platform study’, designed by the leading experts in brain cancer to expedite the approval of new drugs for glioblastoma Multiple drugs can be evaluated in parallel, saving time and money; Bay
Slide 9: GBM AGILE is an adaptive multi-drug registrational study, with strong FDA support
GBM AGILE is an adaptive multi-drug registrational study, with strong FDA support Randomization Drug #2 Drug #3, etc… Drug #1 Common Control Arm Comparison against a common control arm reduces overall subject numbers, saving time and cost (no drug vs. drug comparison) Adaptive study design limits nu
Slide 10: Many biotech companies cannot afford world-class phase III studies
Limited Funding Many biotech companies cannot afford world-class phase III studies More Cost-Effective Approach AGILE achieves huge efficiencies, and is partly grant-funded GBM AGILE directly addresses the key challenges faced by small biotechs and their investors Challenge Approach Long Study Timel
Slide 11: GBM AGILE is currently operational at sites in US and Canada
GBM AGILE is currently operational at 31 sites in US and Canada, and will open EU and China in CY2021 Source: www.gcaresearch.org
Slide 12: Recent regulatory achievements position paxalisib well as it moves towards commercialisation
Recent regulatory achievements position paxalisib well as it moves towards commercialisation Glioblastoma Most common and most aggressive form of brain cancer DIPG Highly aggressive childhood brain cancer Orphan Designation February 2018 August 2020 Rare Pediatric Disease Designation (not applicable
Slide 13: Brain cancer represents a significant commercial opportunity for paxalisib
Brain cancer represents a significant commercial opportunity for paxalisib, with limited competition ~$1.5B+ market opportunity INDICATIVE Glioblastoma 12,500 patients p.a. in the US Brain Metastases (secondary brain cancer) Childhood Brain Cancers Other Adult Primary Brain Cancers Other Cancers wit
Slide 14: Agenda
Agenda Operational Report Financial Report Looking Ahead
Slide 15: Kazia has raised a total of ~AU$ million to drive forward the paxalisib program
Kazia has raised a total of ~AU$ 42 million to drive forward the paxalisib program $3.4 million Institutional Placement October 2018 $0.8 million SPP $4.0 million Institutional Placement October 2019 $7.2 million Institutional Placement April 2020 $1.8 million SPP $22.4 million Institutional Entitle
Slide 16: Almost $0.75 in every dollar the company spends is invested directly into R&D
Almost $0.75 in every dollar the company spends is invested directly into R&D activity AU$ million 4.4 5.9 6.9 5.1 4.5 Expense → ← Income G&A % 44.9% 37.8% 44.1% 27.1% 36.0% bar totals = net expenditure 38.0% 4.1 6.0 6.4 36.0% 20.0%
Slide 17: In the last months, Kazia has achieved a 70% total shareholder return
In the last 12 months, Kazia has achieved a 70% total shareholder return Source: Bloomberg; period is 1 Nov 2019 to 30 Oct 2020 -11% 19% 70%
Slide 18: Kazia's enterprise value has grown from $4M to $36M in four years
Kazia’s enterprise value has grown from $4M to $36M in four years, and is now ~$80M Source: Company Annual Reports; 1Q FY21 Appendix 4C $37M $20M $19M $20M $44M $86M
Slide 19: The company is well covered by sector-leading analysts
The company is well covered by sector-leading analysts
Slide 20: Ongoing UMP facility is part of a long-term program of optimal capital management
Ongoing UMP facility is part of a long-term program of optimal capital management 5,048 126,166,264 51.2% of holders own 0.3% of shares Cost to company (listing fees, report mailing, etc.) Cost to shareholder (brokerage fees to exit position) Unmarketable parcel (UMP) facility is a common capital ma
Slide 21: Agenda
Agenda Operational Report Financial Report Looking Ahead
Slide 22: Key Objectives for CY2021
Key Objectives for CY2021 Execute on GBM AGILE study Drive data from broader paxalisib program Intensify partnering activity Commence ‘rolling NDA’ filing activities
Slide 23: The partnering market for new oncology drugs remains active
The partnering market for new oncology drugs remains active, with a premium for late-stage assets Licensee Licensor Stage Asset(s) Deal Value (US$) Discovery CAR-T platform $900M Discovery T-cell engagers $1,680M Discovery CAR-NK & CAR-T platform $3.1B Phase I CD47 antibody $2,940M Phase I Pralsetin
Slide 24: Key Milestones and Anticipated Newsflow
Key Milestones and Anticipated Newsflow Execution of definitive agreement with GCAR for GBM AGILE pivotal study October 2020 Further interim data from Kazia phase II glioblastoma trial November 2020 Initial interim data from phase I DIPG trial at St Jude November 2020 Initial interim data from phase
Slide 25: ecee” THERAPEUTICS
ee ecee” THERAPEUTICS
Kazia Therapeutics — Shareholder Meeting (November 2020) on 6ix